EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis

Samip Sheth, Joseph F Merola, Brittany N Weber, Ronald Prussick, Jensen Yeung, Clive Liu, Brad Glick, Soumya M Reddy, Fran E Cook-Bolden, Elizabeth Wallace, Michael Garshick, José O Alemán und 3 weitere

JAMA Dermatology · 01.06.2026 · 162 (6) · 619

DOI: 10.1001/jamadermatol.2026.0859 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2026. Verfasst von Samip Sheth und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Department of Internal Medicine, University of Minnesota, Minneapolis. Hauptthemen laut MEDLINE: Psoriasis, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 89 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Psoriasis is a chronic immune-mediated disease associated with cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction–associated steatohepatitis—conditions common in psoriasis. Emerging evidence suggests GLP-1 RAs and dual glucose-dependent insulinotropic polypeptide/GLP-1 agonists may improve psoriatic skin disease, partly through immune modulation. If confirmed in larger randomized clinical trials, GLP-1–based therapies may offer an opportunity to address both cutaneous disease and cardiometabolic comorbidities. This primer from the US National Psoriasis Foundation Medical Board sought to provide an evidence-informed narrative synthesis and practical considerations to introduce dermatologists to GLP-1 RAs for psoriasis treatment. Observations GLP-1 RAs have been associated with reductions in Psoriasis Area and Severity Index (PASI) scores, particularly in patients with obesity or type 2 diabetes. Studies report relative PASI reductions ranging from approximately 40% to 80% with parallel quality-of-life gains, although most of these studies are small (7-48 patients), short term (≤6 months), and lack a control group. Semaglutide and liraglutide have been associated with reductions in C-reactive protein, interleukin-6, lipids, and visceral adiposity. In small, translational cohorts, PASI improvement has been correlated with reductions in superficial adiposity and dermal γδ T-cell density. GLP-1 RAs combine safely with methotrexate, cyclosporine, and biologics. Adverse effects are mainly transient gastrointestinal symptoms; pancreatitis and gallbladder events are rare. Early data show both metabolic and immunomodulatory benefits. Conclusions and Relevance This review found that GLP-1–based therapies target shared metabolic and inflammatory pathways in psoriasis. Current evidence supports consideration of adjunctive use in selected patients with metabolic comorbidities, although definitive conclusions await larger randomized clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisGlucagon-Like Peptide-1 Receptor AgonistsHumansDiabetes Mellitus, Type 2Severity of Illness IndexSemaglutide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • Department of Dermatology and Department of Internal Medicine, University of Minnesota, Minneapolis.
  • Department of Dermatology and Department of Medicine, Division of Rheumatology, University of Texas Southwestern Medical Center and O'Donnell School of Public Health, Dallas.
  • Department of Internal Medicine and Department of Dermatology, Division of Cardiology, Cardio-Dermatology and Cardio-Rheumatology Program, University of Texas Southwestern Medical Center, Dallas.
  • Department of Dermatology, George Washington University School of Medicine, Washington, DC.
  • Department of Dermatology, Division of Medicine, Probity Medical Research, University of Toronto, Toronto, Ontario, Canada.
  • Bellevue Dermatology, Bellevue, Washington.

Zitieren

APA

Sheth, S., Merola, J. F., Weber, B. N., Prussick, R., Yeung, J., Liu, C., Glick, B., Reddy, S. M., Cook-Bolden, F. E., Wallace, E., Garshick, M., Alemán, J. O., Eakin, G. S., Cohen, J. M., & Blauvelt, A. (2026). The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis. JAMA Dermatology, 162(6), 619. https://doi.org/10.1001/jamadermatol.2026.0859

Vancouver

Sheth S, Merola JF, Weber BN, Prussick R, Yeung J, Liu C, et al. The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis. JAMA Dermatology. 2026;162(6):619. doi:10.1001/jamadermatol.2026.0859

BibTeX
@article{Sheth2026,
  author = {Sheth, Samip and Merola, Joseph F and Weber, Brittany N and Prussick, Ronald and Yeung, Jensen and Liu, Clive and Glick, Brad and Reddy, Soumya M and Cook-Bolden, Fran E and Wallace, Elizabeth and Garshick, Michael and Alemán, José O and Eakin, Guy S and Cohen, Jeffrey M and Blauvelt, Andrew},
  title = {The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis},
  journal = {JAMA Dermatology},
  year = {2026},
  volume = {162},
  number = {6},
  pages = {619},
  doi = {10.1001/jamadermatol.2026.0859}
}
Kostenlos starten →